Exclusive Hormonal Therapy in Breast Cancer in Elderly Women: Clinical Response and Survival over 10 Years

Breast cancer is the first cancer of women in the world and in France. In very elderly patients, the treatment options are often very limited. Neoadjuvant hormone therapy has shown similar or even better results than chemotherapy. This is why we decided to evaluate the clinical response following exclusive hormonal therapy and the 5, then 10 years survival in these very elderly women. This was a retrospective, longitudinal cohort-type study with descriptive and analytical purposes. The study population consisted of 59 patients, with an average age of 85 years. Fifteen (15, 25%) of our patients had a complete clinical response after two years of treatment, 16 (27%) a partial clinical response, 23 (39%) lesion stabilization and 5 (9%) cancer progression. The presence of metastasis at diagnosis increased the risk of cancer progression by 2.84. Overall 5-year survival was 72.5%, and breast cancer mortality 5.88%. The 10-year survival was 27.5% and breast cancer mortality 15%. In the age group 85 and over increased the risk of death by 3.25 in the first 10 years of treatment. The clinical response after 2 years was marked by a low rate of cancer progression. Mortality over 5 and 10 years was mostly related to patient comorbidities.